GlassScriptPhysician profile
Frank E Weinholt
NPI 1326126442
$29,216.74
in general payments reported to CMS, 2019-2025
21 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $934 · 2021: $1,931 · 2022: $3,024 · 2023: $1,729 · 2024: $2,172 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,874 · Education: $56.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,874.15 |
| Education | $56.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $16,073.00 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $3,805.43 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $2,058.29 | 2019-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,293.57 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,203.93 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $839.77 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $838.04 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $757.94 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $470.45 | 2022-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $381.29 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $339.17 | 2019-2022 | |
| Lundbeck LLC | $337.41 | 2022-2025 | Rexulti, Brintellix |
| E.R. Squibb & Sons, L.L.C. | $266.77 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $214.15 | 2020-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $98.36 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $91.06 | 2019-2020 | |
| Shire North American Group INC | $76.74 | 2019 | |
| Eisai INC. | $23.20 | 2023 | |
| Indivior INC. | $19.14 | 2022 | |
| Merck Sharp & Dohme LLC | $15.13 | 2020 | |
| Alpha Cognition USA, INC. | $13.90 | 2025 | Zunveyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Weinholt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.